GB2597296A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury

USPTO Abstract

A cannabidiol (CBD) preparation for use in the treatment of seizures associated with bilateral mesial temporal sclerosis (hippocampal sclerosis) is provided. The seizures associated with bilateral mesial temporal sclerosis may be tonic, tonic-clonic and focal seizures with secondary generalisation. The CBD preparation may comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids. The CBD preparation may comprise CBD isolated from cannabis plant material or may be synthetic CBD. The CBD preparation may be used in combination with one or more concomitant anti-epileptic drugs (AED). The one or more concomitant AEDs may be either oxcarbarmazepine or phenobarbital. The dose of CBD may be between 5 mg/kg/day to 50 mg/kg/day. A clinical trial is disclosed wherein a patient diagnosed with bilateral mesial temporal sclerosis had a decrease in the amount of tonic, tonic-clonic and focal seizures secondary generalisation after dosing with the CBD preparation and concomitant AEDs.